- Home
- PETS vs ANIX Comparison
PETS vs ANIX Comparison
Compare PETS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ANIX
- Stock Information
- Founded
- PETS 1996
- ANIX 1982
- Country
- PETS United States
- ANIX United States
- Employees
- PETS N/A
- ANIX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ANIX Health Care
- Exchange
- PETS Nasdaq
- ANIX Nasdaq
- Market Cap
- PETS 82.0M
- ANIX 101.4M
- IPO Year
- PETS N/A
- ANIX 1987
- Fundamental
- Price
- PETS $3.98
- ANIX $3.03
- Analyst Decision
- PETS Sell
- ANIX Strong Buy
- Analyst Count
- PETS 2
- ANIX 2
- Target Price
- PETS $3.50
- ANIX $8.50
- AVG Volume (30 Days)
- PETS 174.8K
- ANIX 42.1K
- Earning Date
- PETS 10-28-2024
- ANIX 10-29-2024
- Dividend Yield
- PETS 28.95%
- ANIX N/A
- EPS Growth
- PETS N/A
- ANIX N/A
- EPS
- PETS N/A
- ANIX N/A
- Revenue
- PETS $270,772,000.00
- ANIX N/A
- Revenue This Year
- PETS N/A
- ANIX N/A
- Revenue Next Year
- PETS $3.27
- ANIX N/A
- P/E Ratio
- PETS N/A
- ANIX N/A
- Revenue Growth
- PETS 2.26
- ANIX N/A
- 52 Week Low
- PETS $2.90
- ANIX $2.15
- 52 Week High
- PETS $10.53
- ANIX $5.13
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- ANIX 43.30
- Support Level
- PETS $3.89
- ANIX $2.95
- Resistance Level
- PETS $4.22
- ANIX $3.11
- Average True Range (ATR)
- PETS 0.20
- ANIX 0.12
- MACD
- PETS -0.02
- ANIX -0.00
- Stochastic Oscillator
- PETS 47.37
- ANIX 30.30
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.